{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:00:58Z","timestamp":1784696458712,"version":"3.55.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00207920"],"award-info":[{"award-number":["RS-2023-00207920"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04418-8","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T07:21:23Z","timestamp":1779348083000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overcoming resistance in CD44-overexpressing myeloma through combination therapy with ATRA, bortezomib, and NK cells"],"prefix":"10.1007","volume":"75","author":[{"given":"Van-Tan","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy Nguyen","family":"Thi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van-Dinh-Huan","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manh-Cuong","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tan-Huy","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Cheol","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga-Young","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo-Yeon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Sook","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deok-Hwan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeoung-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duck","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hoon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"4418_CR1","first-page":"13","volume":"52","author":"K Gee","year":"2004","unstructured":"Gee K, Kryworuchko M, Kumar A (2004) Recent advances in the regulation of CD44 expression and its role in inflammation and autoimmune diseases. Arch Immunol Ther Exp 52:13\u201326","journal-title":"Arch Immunol Ther Exp"},{"issue":"4","key":"4418_CR2","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1182\/bloodadvances.2022007291","volume":"7","author":"J Kikuchi","year":"2023","unstructured":"Kikuchi J, Kodama N, Takeshita M et al (2023) EMD originates from hyaluronan-induced homophilic interactions of CD44 variant-expressing MM cells under shear stress. Blood Adv 7(4):508\u2013524","journal-title":"Blood Adv"},{"key":"4418_CR3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/jop.12478","volume":"46","author":"AM Baschnagel","year":"2017","unstructured":"Baschnagel AM, Tonlaar N, Eskandari M et al (2017) Combined CD44, c-MET, and EGFR expression in p16-positive and p16-negative head and neck squamous cell carcinomas. J Oral Pathol Med 46:208\u2013213","journal-title":"J Oral Pathol Med"},{"key":"4418_CR4","doi-asserted-by":"publisher","first-page":"785192","DOI":"10.3389\/fendo.2021.785192","volume":"12","author":"C Zhao","year":"2022","unstructured":"Zhao C, Zhang Z, Hu X et al (2022) Hyaluronic acid correlates with bone metastasis and predicts poor prognosis in small-cell lung cancer patients. Front Endocrinol 12:785192","journal-title":"Front Endocrinol"},{"issue":"1","key":"4418_CR5","first-page":"2561726","volume":"2020","author":"MA Elbaiomy","year":"2020","unstructured":"Elbaiomy MA, Akl T, Atwan N et al (2020) Clinical Impact of Breast Cancer Stem Cells in Metastatic Breast Cancer Patients. J Oncol 2020(1):2561726","journal-title":"J Oncol"},{"key":"4418_CR6","first-page":"2750","volume":"42","author":"F Negri","year":"2019","unstructured":"Negri F, Bozzetti C, Pedrazzi G et al (2019) High levels of Notch intracellular cleaved domain are associated with stemness and reduced bevacizumab efficacy in patients with advanced colon cancer. Oncol Rep 42:2750\u20132758","journal-title":"Oncol Rep"},{"key":"4418_CR7","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/j.ejso.2021.03.250","volume":"47","author":"J Klose","year":"2021","unstructured":"Klose J, Schmitt A, Pernthaler J et al (2021) Still proliferating CD44(+)\/Ki67(+) tumor cells after neoadjuvant radiochemotherapy identify rectal cancer patients with poor survival. Eur J Surg Oncol 47:2078\u20132086","journal-title":"Eur J Surg Oncol"},{"key":"4418_CR8","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/ijc.29137","volume":"136","author":"S Mikami","year":"2015","unstructured":"Mikami S, Mizuno R, Kosaka T et al (2015) Expression of TNF-alpha and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas. Int J Cancer 136:1504\u20131514","journal-title":"Int J Cancer"},{"key":"4418_CR9","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.1182\/blood-2021-146780","volume":"138","author":"XW Xueqin Ning","year":"2021","unstructured":"Xueqin Ning XW, Chen B et al (2021) CD44 expression in different plasma cell diseases. Blood 138:4754","journal-title":"Blood"},{"issue":"1","key":"4418_CR10","doi-asserted-by":"publisher","first-page":"2087204","DOI":"10.1155\/2016\/2087204","volume":"2016","author":"R Thapa","year":"2016","unstructured":"Thapa R, G W (2016) The importance of CD44 as a stem cell biomarker and therapeutic target in cancer. Stem Cells Int 2016(1):2087204","journal-title":"Stem Cells Int"},{"issue":"1","key":"4418_CR11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s10238-025-01649-4","volume":"25","author":"Z Wang","year":"2025","unstructured":"Wang Z, Y G, Yang C et al (2025) CD44-downregulation in multiple myeloma inhibits cytoskeleton rearrangement through actin depolymerization. Clin Exp Med 25(1):190","journal-title":"Clin Exp Med"},{"key":"4418_CR12","doi-asserted-by":"publisher","first-page":"1613265","DOI":"10.3389\/fimmu.2025.1613265","volume":"16","author":"NT Lannozzi","year":"2025","unstructured":"Lannozzi NT, N G, Storti P (2025) Deciphering the bone marrow microenvironment\u2019s role in multiple myeloma immunotherapy resistance. Front Immunol 16:1613265","journal-title":"Front Immunol"},{"issue":"14","key":"4418_CR13","doi-asserted-by":"publisher","first-page":"e70720","DOI":"10.1111\/jcmm.70720","volume":"29","author":"MTC Mirabile","year":"2025","unstructured":"Mirabile MTC, Neroni A et al (2025) CD44 participates to extramedullary haematopoiesis onset by mediating the interplay between monocytes and haematopoietic stem cells in myelofibrosis. J Cell Mol Med 29(14):e70720","journal-title":"J Cell Mol Med"},{"issue":"2","key":"4418_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/leu.2013.174","volume":"28","author":"CC Bjorklund","year":"2014","unstructured":"Bjorklund CC, Baladandayuthapani V, Lin HY et al (2014) Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia 28(2):373\u2013383","journal-title":"Leukemia"},{"issue":"1","key":"4418_CR15","first-page":"211","volume":"41","author":"SH Cho","year":"2012","unstructured":"Cho SH, Y P, Kim HJ et al (2012) CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion. Int J Oncol 41(1):211\u2013218","journal-title":"Int J Oncol"},{"issue":"23","key":"4418_CR16","doi-asserted-by":"publisher","first-page":"18995","DOI":"10.1074\/jbc.M111.318774","volume":"287","author":"K Miletti-Gonz\u00e1lez","year":"2012","unstructured":"Miletti-Gonz\u00e1lez K, Murphy K, Kumaran MN (2012) Identification of function for CD44 intracytoplasmic domain (CD44-ICD): Modulation of matrix metalloproteinase 9 (MMP-9) transcription via novel promoter response element. J Biol Chem 287(23):18995\u201319007","journal-title":"J Biol Chem"},{"issue":"1","key":"4418_CR17","first-page":"59","volume":"4","author":"JBG Liu","year":"2007","unstructured":"Liu JBG, Wen P et al (2007) Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. Cell Mol Immunol 4(1):59\u201363","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"4418_CR18","first-page":"22","volume":"51","author":"WJDH Fan","year":"2021","unstructured":"Fan WJDH, Chen XX et al (2021) All-trans retinoic acid potentiates antitumor efficacy of cisplatin by increasing differentiation of cancer stem-like cells in cervical cancer. Ann Clin Lab Sci 51(1):22\u201329","journal-title":"Ann Clin Lab Sci"},{"key":"4418_CR19","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1038\/s41467-018-05402-2","volume":"9","author":"S Kozono","year":"2018","unstructured":"Kozono S, Lin YM, Seo HS et al (2018) Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun 9:3069","journal-title":"Nat Commun"},{"issue":"1","key":"4418_CR20","first-page":"5817","volume":"146","author":"LZ Qw","year":"2025","unstructured":"Qw LZ, Xian M et al (2025) All-trans retinoic acid and RAR\u03b2 agonists enhance the efficacy of IMiD-based treatments for t(4;14) multiple myeloma. Blood 146(1):5817","journal-title":"Blood"},{"issue":"1","key":"4418_CR21","first-page":"2052","volume":"144","author":"Z Yinqiang","year":"2024","unstructured":"Yinqiang Z, Wu Z, Wenjing L et al (2024) All-Trans Retinoic Acid Enhances CS1-BCMA Dual-Target CAR-T Cells in Multiple Myeloma. Blood 144(1):2052","journal-title":"Blood"},{"issue":"2","key":"4418_CR22","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3324\/haematol.2022.281339","volume":"108","author":"E Garc\u00eda-Guerrero","year":"2022","unstructured":"Garc\u00eda-Guerrero E, Rodr\u00edguez-Lobato L, Sierro-Mart\u00ednez B et al (2022) All-trans retinoic acid works synergistically with the \u03b3-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells. Haematologica 108(2):568\u2013580","journal-title":"Haematologica"},{"key":"4418_CR23","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3892\/ijo.2016.3806","volume":"50","author":"X Bao","year":"2017","unstructured":"Bao X, Ren T, Huang Y et al (2017) Bortezomib induces apoptosis and suppresses cell growth and metastasis by inactivation of Stat3 signaling in chondrosarcoma. Int J Oncol 50:477\u2013486","journal-title":"Int J Oncol"},{"key":"4418_CR24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/onc.2008.385","volume":"28","author":"K Hatano","year":"2009","unstructured":"Hatano K, Kikuchi J, Takatoku M et al (2009) Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene 28:231\u2013242","journal-title":"Oncogene"},{"issue":"4","key":"4418_CR25","doi-asserted-by":"publisher","first-page":"101070","DOI":"10.1016\/j.gendis.2023.06.037","volume":"11","author":"Z Xiangyi","year":"2024","unstructured":"Xiangyi Z, Ruqing X, Yue W et al (2024) The role of proteasomes in tumorigenesis. Genes & Diseases 11(4):101070","journal-title":"Genes & Diseases"},{"issue":"12","key":"4418_CR26","doi-asserted-by":"publisher","first-page":"4460","DOI":"10.1172\/JCI88152","volume":"126","author":"SHD Alonso","year":"2016","unstructured":"Alonso SHD, Chang YT et al (2016) Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance. J Clin Invest 126(12):4460\u20134468","journal-title":"J Clin Invest"},{"issue":"1","key":"4418_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1182\/blood.2020009856","volume":"139","author":"QLZ Wang","year":"2022","unstructured":"Wang QLZ, Wang Z et al (2022) RAR\u03b3 activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway. Blood 139(1):59\u201372","journal-title":"Blood"},{"issue":"2","key":"4418_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1158\/1535-7163.MCT-12-0433","volume":"12","author":"MZX Ying","year":"2013","unstructured":"Ying MZX, Zhong L et al (2013) Bortezomib sensitizes human acute myeloid leukemia cells to all-trans-retinoic acid-induced differentiation by modifying the RAR\u03b1\/STAT1 axis. Mol Cancer Ther 12(2):195\u2013206","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"4418_CR29","doi-asserted-by":"publisher","first-page":"e27298","DOI":"10.1371\/journal.pone.0027298","volume":"6","author":"P Luo","year":"2011","unstructured":"Luo P, Lin M, Li L et al (2011) The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway. PLoS ONE 6(11):e27298","journal-title":"PLoS ONE"},{"issue":"2","key":"4418_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ccell.2017.06.009","volume":"32","author":"A L\u00f3pez-Soto","year":"2017","unstructured":"L\u00f3pez-Soto A, Gonzalez S, Smyth MJ et al (2017) Control of Metastasis by NK Cells. Cancer Cell 32(2):135\u2013154","journal-title":"Cancer Cell"},{"key":"4418_CR31","doi-asserted-by":"publisher","first-page":"1098445","DOI":"10.3389\/fimmu.2022.1098445","volume":"13","author":"M Vyas","year":"2023","unstructured":"Vyas M, Requesens M, Nguyen TH et al (2023) Natural killer cells suppress cancer metastasis by eliminating circulating cancer cells. Front Immunol 13:1098445","journal-title":"Front Immunol"},{"issue":"1","key":"4418_CR32","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13046-025-03375-x","volume":"44","author":"D Masmoudi","year":"2025","unstructured":"Masmoudi D, Villalba M, Alix-Panabi\u00e8res C (2025) Natural killer cells: the immune frontline against circulating tumor cells. J Exp Clin Cancer Res 44(1):118","journal-title":"J Exp Clin Cancer Res"},{"key":"4418_CR33","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/leu.2008.354","volume":"23","author":"A Poggi","year":"2009","unstructured":"Poggi A, Catellani S, Garuti A et al (2009) Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia 23:641\u2013648","journal-title":"Leukemia"},{"key":"4418_CR34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3892\/or.2016.5212","volume":"37","author":"H Zou","year":"2017","unstructured":"Zou H, Li L, Han Y et al (2017) Upregulation of CD54 and downregulation of HLA-ABC contribute to the novel enhancement of the susceptibility of HL-60 cells to NK cell-mediated cytolysis induced by ATRA plus VPA. Oncol Rep 37:105\u2013114","journal-title":"Oncol Rep"},{"issue":"3","key":"4418_CR35","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1182\/blood-2007-03-078535","volume":"111","author":"GJT Jumei Shi","year":"2008","unstructured":"Jumei Shi GJT, Garg TK et al (2008) Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell\u2013mediated lysis of myeloma. Blood 111(3):1309\u20131317","journal-title":"Blood"},{"issue":"7","key":"4418_CR36","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1038\/s41423-021-00686-9","volume":"18","author":"JLAS Thangaraj","year":"2021","unstructured":"Thangaraj JLAS, Jung SH et al (2021) Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model. Cell Mol Immunol 18(7):1652\u20131661","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"4418_CR37","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00262-021-02982-9","volume":"71","author":"JLPM Thangaraj","year":"2022","unstructured":"Thangaraj JLPM, Kweon S et al (2022) Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21. Cancer Immunol Immunother 71(3):613\u2013625","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"4418_CR38","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00262-022-03322-1","volume":"72","author":"J Thangaraj","year":"2023","unstructured":"Thangaraj J, Jung SH, Vo MC (2023) Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model. Cancer Immunol Immunother 72(5):1233\u20131246","journal-title":"Cancer Immunol Immunother"},{"issue":"1\u20132","key":"4418_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jim.2004.11.021","volume":"297","author":"C Brown","year":"2005","unstructured":"Brown C, Wright C, Naranjo A et al (2005) Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing. J Immunol Methods 297(1\u20132):39\u201352","journal-title":"J Immunol Methods"},{"key":"4418_CR40","unstructured":"CoMMpass from the UCSC Xena was accessed on 2025.05.30 [Available from: https:\/\/xenabrowser.net\/]."},{"key":"4418_CR41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12935-017-0393-y","volume":"17","author":"GJ Yoshida","year":"2017","unstructured":"Yoshida GJ (2017) The heterogeneity of cancer stem-like cells at the invasive front. Cancer Cell Int 17:23","journal-title":"Cancer Cell Int"},{"key":"4418_CR42","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.3892\/ijo.2016.3480","volume":"48","author":"CZY Wu","year":"2016","unstructured":"Wu CZY, Jiang S (2016) Interaction between Wnt\/\u03b2-catenin pathway and microRNAs regulates epithelial-mesenchymal transition in gastric cancer. Int J Oncol 48:2236\u20132246","journal-title":"Int J Oncol"},{"key":"4418_CR43","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12935-025-03748-4","volume":"25","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Li SY, Yang SS et al (2025) CD44 on cancer stem cell is a potential immunological and prognostic pan-cancer biomarker. Cancer Cell Int 25:134","journal-title":"Cancer Cell Int"},{"issue":"1","key":"4418_CR44","doi-asserted-by":"publisher","first-page":"7011","DOI":"10.1038\/s41598-023-34154-3","volume":"13","author":"SZS Chen","year":"2023","unstructured":"Chen SZS, Chen S, Ma F (2023) The prognostic value and immunological role of CD44 in pan-cancer study. Sci Rep 13(1):7011","journal-title":"Sci Rep"},{"issue":"4","key":"4418_CR45","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/cyto.b.21083","volume":"84","author":"W Zheng","year":"2013","unstructured":"Zheng W, Liu D, Fan X et al (2013) Potential therapeutic biomarkers in plasma cell myeloma: a flow cytometry study. Cytometry B Clin Cytom 84(4):222\u2013228","journal-title":"Cytometry B Clin Cytom"},{"issue":"4","key":"4418_CR46","first-page":"1297","volume":"109","author":"L Notarfranchi","year":"2024","unstructured":"Notarfranchi L, Accardi F, Mancini C, Martella E, Bonomini S, Segreto R et al (2024) CD38 expression by plasma cells in extramedullary multiple myeloma. Haematologica 109(4):1297\u20131300","journal-title":"Haematologica"},{"key":"4418_CR47","doi-asserted-by":"publisher","first-page":"1254612","DOI":"10.3389\/fcell.2023.1254612","volume":"11","author":"KNS Lavudi","year":"2023","unstructured":"Lavudi KNS, Olverson Z et al (2023) Targeting the retinoic acid signaling pathway as a modern precision therapy against cancers. Front Cell Dev Biol 11:1254612","journal-title":"Front Cell Dev Biol"},{"issue":"22","key":"4418_CR48","doi-asserted-by":"publisher","first-page":"16466","DOI":"10.3390\/ijms242216466","volume":"24","author":"AEN Dabrock","year":"2023","unstructured":"Dabrock AEN, Will F et al (2023) RAR-dependent and RAR-independent RXR signaling in stem-like glioma cells. Int J Mol Sci 24(22):16466","journal-title":"Int J Mol Sci"},{"key":"4418_CR49","doi-asserted-by":"publisher","first-page":"1676945","DOI":"10.3389\/fcell.2025.1676945","volume":"13","author":"A Guha","year":"2025","unstructured":"Guha A, Banerjee S (2025) Trogocytosis at the crossroad of cancer and immunity: mechanisms, implications and therapeutic perspectives. Front Cell Dev Biol 13:1676945","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"4418_CR50","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3324\/haematol.12349","volume":"93","author":"H Rozemuller","year":"2008","unstructured":"Rozemuller H, van der Spek E, Bogers-Boer LH et al (2008) A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect. Haematologica 93(7):1049\u20131057","journal-title":"Haematologica"},{"issue":"7","key":"4418_CR51","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3324\/haematol.2011.054254","volume":"97","author":"BEWB Swift","year":"2012","unstructured":"Swift BEWB, Kosaka Y et al (2012) Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. Haematologica 97(7):1020\u20131028","journal-title":"Haematologica"},{"issue":"12","key":"4418_CR52","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1002\/jbmr.3859","volume":"34","author":"ACLD Green","year":"2019","unstructured":"Green ACLD, Hudson K et al (2019) TGF\u03b2 inhibition stimulates collagen maturation to enhance bone repair and fracture resistance in a murine myeloma model. J Bone Miner Res 34(12):2311\u20132326","journal-title":"J Bone Miner Res"},{"issue":"7","key":"4418_CR53","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1158\/1535-7163.MCT-21-0552","volume":"21","author":"JMEJ Buonato","year":"2022","unstructured":"Buonato JMEJ, Zaritskaya L et al (2022) Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain. Mol Cancer Ther 21(7):1171\u20131183","journal-title":"Mol Cancer Ther"},{"key":"4418_CR54","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3389\/fimmu.2017.00458","volume":"8","author":"MWJ Granzin","year":"2017","unstructured":"Granzin MWJ, K\u00f6hl U (2017) Shaping of natural killer cell antitumor activity by ex vivo cultivation. Front Immunol 8:458","journal-title":"Front Immunol"},{"key":"4418_CR55","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3389\/fimmu.2015.00578","volume":"6","author":"KRR Rezvani","year":"2015","unstructured":"Rezvani KRR (2015) The application of natural killer cell immunotherapy for the treatment of cancer. Front Immunol 6:578","journal-title":"Front Immunol"},{"issue":"12","key":"4418_CR56","doi-asserted-by":"publisher","first-page":"e1250051","DOI":"10.1080\/2162402X.2016.1250051","volume":"5","author":"LA P-Ma","year":"2016","unstructured":"P-Ma LA, Blanchard MJ (2016) Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma. Oncoimmunology 5(12):e1250051","journal-title":"Oncoimmunology"},{"issue":"20","key":"4418_CR57","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","volume":"122","author":"Monica Casucci BNdR","year":"2013","unstructured":"Monica Casucci BNdR (2013) Laura falcone, CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood 122(20):3461\u20133472","journal-title":"Blood"},{"key":"4418_CR58","doi-asserted-by":"publisher","first-page":"1290488","DOI":"10.3389\/fimmu.2023.1290488","volume":"14","author":"ISFJ Ciulean","year":"2023","unstructured":"Ciulean ISFJ, Quaiser A (2023) CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma. Front Immunol 14:1290488","journal-title":"Front Immunol"},{"issue":"10","key":"4418_CR59","doi-asserted-by":"publisher","first-page":"9038","DOI":"10.3390\/ijms24109038","volume":"24","author":"MJFA Raftery","year":"2023","unstructured":"Raftery MJFA, Radecke C (2023) Next generation CD44v6-specific CAR-NK cells effective against triple negative breast cancer. Int J Mol Sci 24(10):9038","journal-title":"Int J Mol Sci"},{"issue":"14","key":"4418_CR60","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1182\/blood.2025028330","volume":"146","author":"MGN Merz","year":"2025","unstructured":"Merz MGN, Smaili S (2025) Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST. Blood 146(14):1677\u20131686","journal-title":"Blood"},{"key":"4418_CR61","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.1182\/bloodadvances.2020002547","volume":"4","author":"RDM Basar","year":"2020","unstructured":"Basar RDM, Rezvani K (2020) Next-generation cell therapies: the emerging role of CAR-NK cells. Blood Adv 4:5868\u20135876","journal-title":"Blood Adv"},{"key":"4418_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01083-5","author":"GY Kwr","year":"2021","unstructured":"Kwr GY, Wang J (2021) Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. https:\/\/doi.org\/10.1186\/s13045-021-01083-5","journal-title":"J Hematol Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04418-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04418-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04418-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:03:17Z","timestamp":1784692997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04418-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":62,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["4418"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04418-8","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"6 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflict of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used cryopreserved peripheral blood and bone marrow samples that were collected from patients after obtaining informed consent and stored at human biobank in Chonnam National University Hwasun Hospital.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Patient consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures were approved by the Institutional Animal Care and Use Committee of Chonnam National University Medical School (CNU IACUC-H2022-35).","order":4,"name":"Ethics","label":"Human or animal rights","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"189"}}